Cost-effectiveness of edaravone dexborneol sublingual tablet versus concentrated solution for injection for the treatment of acute ischemic stroke in China
EDSL represents a more cost-effective therapy for AIS patients compared to EDCSI, offering comparable efficacy at a lower drug cost. A full 14-day treatment course may help maximize patient benefits.
Authors
- Fan Xie
- Yuqiong Lu (ORCID: https://orcid.org/0000-0002-8175-3949)
- Yan Bao (ORCID: https://orcid.org/0000-0002-5907-3955)
- Yanlei Zhang (ORCID: https://orcid.org/0000-0003-1536-386X)
- Zhuo Yang (ORCID: https://orcid.org/0000-0002-5296-8596)
- Yun Lu
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.3389/fphar.2025.1661581
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation
- Government of Jiangsu Province